

1 **CHARACTERIZATION OF RARE *ABCC8* VARIANTS IDENTIFIED IN SPANISH**

2 **PULMONARY ARTERIAL HYPERTENSION PATIENTS**

3 Mauro Lago-Docampo<sup>1,2</sup>; Jair Tenorio<sup>3,4,5</sup>; Ignacio González-Hernández<sup>6,7,8</sup>, Carmen Pérez-  
4 Olivares<sup>7,8,9</sup>, Pilar Escribano-Subías<sup>7,8,9</sup>; Guillermo Pousada<sup>2</sup>, Adolfo Baloira<sup>10</sup>; Miguel Arenas<sup>1,2</sup>;  
5 Pablo Lapunzina<sup>3,4,5</sup>; Diana Valverde<sup>1,2\*</sup>

6

7 <sup>1</sup> CINBIO, Universidade de Vigo, Vigo, Spain.

8 <sup>2</sup> Instituto de Investigación Sanitaria Galicia Sur, Hospital Álvaro Cunqueiro, Vigo, Spain.

9 <sup>3</sup> Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz-IdiPaz,  
10 Universidad Autónoma de Madrid, Madrid, Spain.

11 <sup>4</sup> Centro de Investigación Biomédica en Red de enfermedades Raras (CIBERER), Instituto de  
12 Salud Carlos III, Madrid, Spain.

13 <sup>5</sup> ITHACA, European Reference Network on Rare Congenital Malformations and Rare  
14 Intellectual Disability.

15 <sup>6</sup> Servicio de Cardiología, Hospital Universitario Río Hortega, Valladolid, Spain.

16 <sup>7</sup> Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV),  
17 Instituto de Salud Carlos III, Madrid, Spain.

18 <sup>8</sup> Unidad Multidisciplinar de Hipertensión Pulmonar, Servicio de Cardiología, Hospital  
19 Universitario 12 de Octubre, Madrid, Spain

20 <sup>9</sup> Servicio de Cardiología, Hospital 12 de Octubre, Madrid, Spain

21 <sup>10</sup> Servicio de Neumología, Complejo Hospitalario de Pontevedra, Pontevedra, Spain.

22

23 **\*Corresponding Author:**

24 Dr. Diana Valverde. Departamento de Bioquímica, Genética e Inmunología. Universidad de  
25 Vigo, Campus Universitario As Lagoas-Marcosende s/n, Facultad de Biología, Vigo 36310  
26 (Spain).

27 Phone number: (+34) 986 811 953 / e-mail: [dianaval@uvigo.es](mailto:dianaval@uvigo.es)

28 **SUPPLEMENTARY INFORMATION**

29 **SUPPLEMENTARY TABLE 1. Baseline characteristics of the studied cohort.** Data shows absolute number ( $\pm$  refers to standard deviation).

<b>Baseline characteristics</b>	<b>Adult cohort</b>	<b>Pediatric cohort</b>
Age, years	45 ( $\pm$ 0,76)	9.9 ( $\pm$ 4.4)
Female sex	411 (71 %)	27 (60 %)
<b>Etiology</b>		
Idiopathic	262 (45.25 %)	23 (51.1 %)
Familial	31 (5.35 %)	4 (8.9 %)
Pulmonary Venocclusive Disease	54 (9.33 %)	3 (6.7 %)
Connective Tissue Disease	91 (15.72 %)	-
Congenital Heart Disease	88 (15.2 %)	11 (24.4 %)
Drugs	22 (3.8 %)	-
Portopulmonary Hypertension	11 (1.9 %)	-
Hereditary Hemorrhagic Telangiectasia	7 (1.21 %)	-
Human Immunodeficiency Virus	13 (2.25 %)	-
Other	-	4 (8.9 %)

<b>Race</b>		
White	510 (88.1 %)	39 (86.7 %)
Hispanic	37 (6.4 %)	3 (6.7 %)
Romani	23 (4 %)	3 (6.7 %)
Black	1 (0.2 %)	-
North African	6 (1%)	-
Asian	1 (0.2 %)	-
Hindu	1 (0.2 %)	-

30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 **SUPPLEMENTARY TABLE 2. List of primers used for the minigene assay and the site directed mutagenesis.** The temperature used to amplify the constructs is also given. F  
 46 = Forward and R = Reverse, bp = base pairs.

Target	Minigene Construct Primers 5' - 3'	Mutagenesis Primers 5' - 3'	Size (bp)	PCR °C
<b>c.211C&gt;T p.(His71Tyr)</b>	F - AAACCTCGAGGGGGAGGTACCAGCATAGGA	F - GCTTCATTTCCCTGGGTACAACCTGCGGTGGATCC	674	55
	R - AAAGCTAGCAAGGTAACCTCCGGCAGGTTG	R - GGATCCACCGCAGGTTGTACCCAGGGAAATGAAGC		
<b>c.298G&gt;A p.(Glu100Lys)</b>	F - CACGAATTCATGGGAGACTAAGAGTACCCAC	F - GCAGATGGTGGGATTTGGTCACCCTGAGATG	1021	60
	R - AAAGCTAGCTTTGCCACAGTGACATCTT	R - CATCTCAGGGTGACCAAATCCCACCATCTGC		
<b>c.1429G&gt;A p.(Val477Met)</b>	F - CCAGAATTCCTCTGCTTGCATGAGAG	F - CCTGTCCAGTACTTCATGGCCACCAAGCTG	1173	60
	R - AAAGCTAGCAGCACATAGCAGGCTTTCCA	R - CAGCTTGGTGGCCATGAAGTACTGGACAGG		
<b>c.1643C&gt;T p.(Thr548Met)</b>	F - AAAACTCGAGCCTAGCCTACTGGAGCTGTGC	-	403	65
	R - AAAAGCTAGCCTAAGCCTCCGGTCTTCCAG	-		
<b>c.2422C&gt;A p.(Gln808Lys)</b>	F - ACAGGATCCCCAACCAATTCATCCTTC	F - GAAGCTGCTCTCTGAAGCCAGACATCGACA	1227	61.5
	R - AAAGCTAGCCCTGCCTCAGTTTCCCTATC	R - TGTCGATGTCTGGCTTCAGAGAGCAGGCTTC		
<b>c.2694+1G&gt;A</b>	F - AAAAGCTAGCGACAACGGATTGGTTCCTGCC	-	482	65
	R - AAAACTCGAGGTTGAAGGTCCAGGAGTCAGG	-		
<b>c.3288_3289del p.(His1097ProfsTer16)</b>	F - CCAGAATTCCTGGCAAGATGAATGTGTGTC	F - TGAAGGTGGCCAAGAGACTACCGCAGCCT	1177	60.5
	R - AAAGCTAGCGCTAACCCACACACAATGCCT	R - AGGCTGCGGTAGTCTCTTGGCCACCTTCA		
<b>c.3394G&gt;A p.(Asp1132Asn)</b>	F - AAAACTCGAGAAATTGGCAGAGGATGCCAGA	-	351	65
	R - AAAAGCTAGCTAATCGGATCGGGGACACTG	-		
<b>c.3976G&gt;A p.(Glu1326Lys)</b>	F - ACAGAATTCCTTCGCAGCCCTTGTGTGTG	F - CCCAGGAGCCCCTTGTAGCTCTCTGCC	1296	63
	R - AAAGCTAGCGTCCGGTCTCCTTGGTGGATGAG	R - GGCAGAGAGCTACAAGGGGCTCCTGGG		

47

48

49

50

51 **SUPPLEMENTARY TABLE 3. List of transcription factors binding in each Genehancer region.** All the data is available in the Genecards *ABCC8* entry  
 52 (<https://www.genecards.org/cgi-bin/carddisp.pl?gene=ABCC8>).

Genehancer	Transcription Factor Binding sites
<b>GH11J017401</b>	-
<b>GH11J017404</b>	HDAC1, FOXA2, NFXL1, RAD21, YY1, ZNF766, EGR1, RCOR1, IKZF2, RXRA, REST, NR2F2, SREBF1, SP1, IKZF1, ZBTB33, HNF4A, KDM1A, CTCF, BCOR, NCOA3, ZMYM3, MAX, BACH1, EBF1, ZNF316, CTBP1, POLR2A, HNF4G, NFE2, MAFK, NR2F1, MAFG, MEF2B, GABPA, XRCC5, JUND, ATF3, ZFX, EMSY
<b>GH11J017411</b>	ZNF664, ZFHX2, NFIC, ZNF189, NFIB, IKZF1, EGR2
<b>GH11J017412</b>	CTCF, RXRA, MAFG, CBFA2T3, RFX5, YY1, SP1, MAFF, ZNF316, CBFA2T2, HNF4A, MAFK, EMSY
<b>GH11J017432</b>	ZFHX2, KLF1, EGR2

53


54 **SUPPLEMENTARY TABLE 4. MaxEntScan of the exons from the minigene constructs.** Capital letters represent exonic sequence while lower letters represent intronic  
 55 sequence.

Variant	First Exon	Donor sequence	Score	Last Exon	Acceptor Sequence	Score	Minigene
<b>c.211C&gt;T:p.(His71Tyr):</b>	<b>2</b>	TGGGGAAGT	<b>2.59</b>	<b>2</b>	TGGgtgagt	<b>8.73</b>	<b>worked</b>
<b>c.298G&gt;A:p.Glu100Lys</b>	<b>3</b>	agGGTGACC	<b>2.27</b>	<b>3</b>	CCCAAGCTGCTAATTGgtaggtg	<b>0.51</b>	<b>worked</b>
<b>c.1429G&gt;A:p.Val477Met</b>	<b>9</b>	accctgacccttctcagATC	<b>7.68</b>	<b>10</b>	CCAgtagagt	<b>8.28</b>	<b>worked</b>
<b>c.1643C&gt;T:p.(Thr548Met)</b>	<b>11</b>	TCCCTGTGCTTCTCTGCAGTTT	<b>10.38</b>	<b>11</b>	ATAGTAAGT	<b>8.64</b>	not worked
<b>c.2422C&gt;A:p.(Gln808Lys)</b>	<b>20</b>	cagGTACAA	<b>7.09</b>	<b>21</b>	TTGgtgagt	<b>9.27</b>	not worked
<b>c.2694+1G&gt;A</b>	<b>22</b>	ttcctctcccttctgccagGAT	<b>8.34</b>	<b>22</b>	TGGgtgag	<b>6.74</b>	not worked
<b>c.3288_3289del:p.(His1097ProfsTer16)</b>	<b>24</b>	aggccacatctgtcttttagGAG	<b>7.06</b>	<b>26</b>	GAGgtacc	<b>7.84</b>	not worked
<b>c.3394G&gt;A:p.Asp1132Asn</b>	<b>27</b>	CCTGGTCGATGGTGTACAGTCA	<b>4.5</b>	<b>27</b>	AAGGGGCGT	<b>1.84</b>	<b>worked</b>
<b>c.3976G&gt;A:p.(Glu1326Lys)</b>	<b>31</b>	cagctctctccctcccagGAG	<b>9.78</b>	<b>33</b>	AAGgtcaga	<b>6.7</b>	not worked


56

57

**SUPPLEMENTARY FIGURE 1. UCSC genome browser entry for *ABCC8* focusing on regulatory elements.** Genehancer positions are marked with their codes.




**SUPPLEMENTARY FIGURE 2. Protein stability analysis of the variants and the original model.** Comparison of the stability of the models and the template used to generate them. All the models show less stability than the template 6C3O, expected when comparing simulated data and an experimentally generated template (Gray for skipping models and black for missense).




**Gels depicted in Figure 2.**


**Exon 2 minigene wild type and mutated.**




**Minigene exon 3 wild type and mutated.**




**Minigene exons 9 and 10 WT (wells 2, 3 and 4).** The wells 6, 7 and 8 correspond to the minigene for exon 20. The band on the right corner corresponds to a degraded DNA ladder.



**Minigene for exon 9 and 10 after mutagenesis**



**Minigene for exon 27 (right corner), cropped in figure 2.**



**Illustrative minigene for figure 2E.** It shows the minigenes for exon 11 (wild type and mutated) and exon 26 (wild type and mutated) respectively.

